Highlights
• In a multicenter randomized placebo-controlled trial, 200 IU/day natural vitamin E lowered ALT nearly as much as 400 IU/day and 800 IU/day in adults with suspected MASH and elevated aminotransferases.
• ALT normalization was more frequent with vitamin E than placebo, while liver fat and stiffness improved numerically but not significantly.
• Safety signals were not observed over 24 weeks, suggesting that a lower dose may preserve biochemical benefit while limiting theoretical dose-related risks.
Study Background
MASLD, formerly termed NAFLD, is now recognized as a major cause of chronic liver disease worldwide. A clinically important subset of patients develops steatohepatitis, now often referred to as MASH, which carries a higher risk of fibrosis progression, cirrhosis, and liver-related morbidity. Despite advances in pharmacotherapy, there remains a strong need for accessible, low-cost treatments that can be used broadly in routine practice.
Vitamin E has long been considered a potential therapy for noncirrhotic MASH, largely on the basis of its antioxidant properties and prior randomized trial evidence showing histologic and biochemical improvement in selected patients. However, the commonly used 800 IU/day dose has raised concerns about long-term safety, including potential associations with bleeding risk and other adverse outcomes in some non-hepatic studies. The VEDS trial was designed to test whether lower doses might deliver similar biochemical benefit with a more favorable risk-benefit profile.
Study Design
The Vitamin E Dosing Study (VEDS) was a multicenter, randomized, placebo-controlled trial published in Hepatology. Adults with suspected MASH were eligible if they had a controlled attenuation parameter (CAP) score greater than 280 dB/m on vibration-controlled transient elastography and serum alanine aminotransferase (ALT) at least 60 U/L. These criteria enriched for patients with hepatic steatosis and active liver injury.
Participants were randomized to receive once-daily natural vitamin E (d-alpha tocopherol) at 200 IU, 400 IU, or 800 IU, or placebo, for 24 weeks. The primary endpoint was the change in ALT from baseline to week 24, with the goal of identifying the lowest effective dose that produced the greatest ALT reduction. Secondary outcomes included other biochemical measures, as well as noninvasive indicators of liver fat and stiffness.
Key Findings
A total of 200 participants completed protocol-based visits. The mean age was 47.0 years, and 62% were male, reflecting a middle-aged population typical of clinical MASLD cohorts. Over the 24-week treatment period, ALT levels fell substantially in all vitamin E groups and much less in the placebo group.
Compared with placebo, ALT decreased by 38% with 200 IU/day, 36% with 400 IU/day, and 36% with 800 IU/day. All comparisons with placebo were statistically significant, with p≤0.001. The most clinically important observation was that the lowest dose, 200 IU/day, was not inferior in practical terms to the higher doses for the primary biochemical endpoint. The data do not suggest a dose-response advantage for increasing vitamin E beyond 200 IU/day within the 24-week observation window.
ALT normalization, a useful but imperfect surrogate of hepatic improvement, occurred in 49% of patients receiving 200 IU/day, 37% receiving 400 IU/day, and 50% receiving 800 IU/day, compared with 22% in the placebo group. AST also declined significantly in vitamin E-treated participants, reinforcing the biochemical signal that hepatic inflammation or injury improved during treatment.
Secondary measures of liver fat and stiffness showed favorable numerical trends, with mean reductions in CAP and liver stiffness greater in vitamin E groups than in placebo. However, these changes did not reach statistical significance. This is an important nuance: while the trial supports a clear ALT-lowering effect, it does not establish that vitamin E at any tested dose meaningfully improves fibrosis-related risk over 24 weeks. Given that fibrosis regression usually requires longer follow-up and histologic assessment, the noninvasive endpoint findings should be interpreted cautiously.
Safety outcomes were reassuring. Adverse events were generally mild to moderate, no life-threatening events were reported, and overall adverse event rates were similar across vitamin E and placebo groups. Within the time frame studied, there was no evidence that higher vitamin E doses produced more harm. Still, absence of short-term harm does not eliminate concern about longer-term risks, particularly in populations that might remain on therapy for months or years.
Clinical Interpretation
The main practical message from VEDS is straightforward: in patients with suspected MASH and elevated ALT, 200 IU/day of natural vitamin E appears to deliver a biochemical response comparable to 400 IU/day and 800 IU/day over 24 weeks. This matters because lower-dose strategies may reduce cost, improve acceptability, and potentially lessen exposure to dose-related adverse effects.
That said, the study’s primary endpoint was ALT, not histologic improvement. ALT is a convenient and widely used biomarker, but it is an imperfect surrogate for liver disease activity and does not reliably quantify fibrosis. A drop in ALT supports improvement in hepatocellular injury, yet it does not prove reduced progression to cirrhosis or lower clinical event rates. Thus, the trial strengthens the case for vitamin E as a biochemical treatment option, but it does not redefine vitamin E as a disease-modifying therapy with proven long-term outcome benefits.
The patient population also deserves attention. The study enrolled adults with suspected MASH, CAP >280 dB/m, and ALT ≥60 U/L, which identifies a group with substantial steatosis and biochemical activity, but not necessarily biopsy-proven steatohepatitis. As a result, the findings are highly relevant to real-world hepatology practice, where noninvasive testing often guides decisions, but they may not generalize perfectly to all MASLD phenotypes, especially those with normal ALT, advanced fibrosis, or established cirrhosis.
Expert Commentary
VEDS fits into a broader therapeutic landscape in which MASH treatment is increasingly individualized. Recent drug approvals have improved the outlook for selected patients, yet access, cost, and tolerability remain major barriers. A low-cost agent with a measurable biochemical effect remains attractive, particularly when used in conjunction with weight loss, exercise, metabolic risk reduction, and treatment of diabetes, dyslipidemia, and obesity.
From a mechanistic standpoint, vitamin E may reduce oxidative stress and lipid peroxidation, pathways implicated in steatohepatitis. The trial’s findings are biologically plausible and consistent with prior evidence, including the PIVENS trial, which showed histologic benefit of vitamin E in nondiabetic adults with biopsy-proven NASH. However, VEDS differs from PIVENS in an important way: it focuses on dose optimization and uses modern noninvasive enrollment criteria, making it more relevant to current practice but less definitive for histologic efficacy.
Several limitations temper enthusiasm. The follow-up period was only 24 weeks, which is short for a chronic liver disease where fibrosis progression and clinical outcomes evolve over years. The use of ALT as the primary endpoint limits inference about longer-term disease modification. The trial also did not provide evidence that higher doses confer any incremental benefit, but it cannot exclude the possibility that longer exposure might reveal differences in histology or fibrosis-related outcomes. Finally, while adverse events were similar over the study duration, longer-term safety remains important, particularly if vitamin E is used chronically.
Guideline recommendations have historically been cautious and selective regarding vitamin E, typically reserving it for carefully chosen patients with noncirrhotic MASH, often without diabetes, and after discussion of uncertain long-term benefit and potential safety concerns. The VEDS data support reconsidering the dose if vitamin E is used, but they do not broaden indications beyond the evidence base for patients most likely to benefit.
Conclusion
VEDS provides a clinically useful dose-finding message: 200 IU/day of natural vitamin E achieved ALT reductions similar to 400 IU/day and 800 IU/day in adults with suspected MASH and elevated aminotransferases, with no short-term safety penalty observed. For clinicians, this supports the idea that lower-dose vitamin E may be sufficient for biochemical improvement when the drug is used as part of a broader MASLD management strategy.
What remains unresolved is whether vitamin E meaningfully alters fibrosis, clinical events, or long-term outcomes, and whether the apparent equivalence among doses persists beyond 24 weeks. Future studies with histologic endpoints, longer follow-up, and better linkage to fibrosis outcomes will be needed before vitamin E can be positioned as more than a short-term biochemical therapy.
Funding and Trial Registration
The citation identifies the study as a multicenter, randomized, placebo-controlled trial conducted by the NASH Clinical Research Network and published in Hepatology. The abstract provided does not include funding details or a clinicaltrials.gov identifier; these should be verified in the full text or trial registry entry before citation in formal clinical documents.
References
1. Dasarathy S, Mitchell EP, Wilson LA, Neuschwander-Tetri BA, Chalasani N, Clark JM, Diehl AM, Hameed B, Loomba R, Yuan L, Kowdley KV, Sanyal AJ, NASH Clinical Research Network. Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial. Hepatology. 2026-06-09. PMID: 42268981.
2. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685.
3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357.
4. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-1986.